187 related articles for article (PubMed ID: 37347391)
1. Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours.
Yen CC; Yeh YM; Huang HY; Ting YL; Fu PA; Lin TC; Liu IT; Yen CJ
Target Oncol; 2023 Jul; 18(4):611-623. PubMed ID: 37347391
[TBL] [Abstract][Full Text] [Related]
2. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.
Lu C; Dong XR; Zhao J; Zhang XC; Chen HJ; Zhou Q; Tu HY; Ai XH; Chen XF; An GL; Bai J; Shan JL; Wang YN; Yang SY; Liu X; Zhuang W; Wu HT; Zhu B; Xia XF; Chen RR; Gu DJ; Xu HM; Wu YL; Yang JJ
J Hematol Oncol; 2020 Apr; 13(1):37. PubMed ID: 32295619
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of immune checkpoint inhibitor therapy in patients with
Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
[TBL] [Abstract][Full Text] [Related]
4. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
5. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Hegde A; Andreev-Drakhlin AY; Roszik J; Huang L; Liu S; Hess K; Cabanillas M; Hu MI; Busaidy NL; Sherman SI; Dadu R; Grubbs EG; Ali SM; Lee J; Elamin YY; Simon GR; Blumenschein GR; Papadimitrakopoulou VA; Hong D; Meric-Bernstam F; Heymach J; Subbiah V
ESMO Open; 2020 Oct; 5(5):e000799. PubMed ID: 33097651
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.
Uehara Y; Watanabe K; Hakozaki T; Yomota M; Hosomi Y
Thorac Cancer; 2022 Jun; 13(11):1703-1711. PubMed ID: 35491960
[TBL] [Abstract][Full Text] [Related]
7. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
10. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Drilon A; Hu ZI; Lai GGY; Tan DSW
Nat Rev Clin Oncol; 2018 Mar; 15(3):151-167. PubMed ID: 29134959
[TBL] [Abstract][Full Text] [Related]
11. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract][Full Text] [Related]
12. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
Michels S; Scheel AH; Scheffler M; Schultheis AM; Gautschi O; Aebersold F; Diebold J; Pall G; Rothschild S; Bubendorf L; Hartmann W; Heukamp L; Schildhaus HU; Fassunke J; Ihle MA; Künstlinger H; Heydt C; Fischer R; Nogovà L; Mattonet C; Hein R; Adams A; Gerigk U; Schulte W; Lüders H; Grohé C; Graeven U; Müller-Naendrup C; Draube A; Kambartel KO; Krüger S; Schulze-Olden S; Serke M; Engel-Riedel W; Kaminsky B; Randerath W; Merkelbach-Bruse S; Büttner R; Wolf J
J Thorac Oncol; 2016 Jan; 11(1):122-7. PubMed ID: 26762747
[TBL] [Abstract][Full Text] [Related]
14. Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement.
Gao QY; Xiao FM; Lin XC; Chen YQ; Li YF; Lu C; Su JW; Tan QQ; Zhang CY; Yang J; Wu YL; Chen HJ; Yang JJ
Cancer Treat Res Commun; 2023; 35():100707. PubMed ID: 37121144
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
17. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W
Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967
[TBL] [Abstract][Full Text] [Related]
18. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
[TBL] [Abstract][Full Text] [Related]
19. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
20. Hallmarks of RET and Co-occuring Genomic Alterations in
Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
